The Growth and Potential of Human Antiviral Monoclonal Antibody Therapeutics

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2007 Dec 11

PMID 18066039

Citations 141

Authors

Wayne A Marasco

Jianhua Sui

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies (mAbs) have long provided powerful research tools for virologists to understand the mechanisms of virus entry into host cells and of antiviral immunity. Even so, commercial development of human (or humanized) mAbs for the prophylaxis, preemptive and acute treatment of viral infections has been slow. This is surprising, as new antibody discovery tools have increased the speed and precision with which potent neutralizing human antiviral mAbs can be identified. As longstanding barriers to antiviral mAb development, such as antigenic variability of circulating viral strains and the ability of viruses to undergo neutralization escape, are being overcome, deeper insight into the mechanisms of mAb action and engineering of effector functions are also improving the efficacy of antiviral mAbs. These successes, in both industrial and academic laboratories, coupled with ongoing changes in the biomedical and regulatory environments, herald an era when the commercial development of human antiviral mAb therapies will likely surge.

Citing Articles

Recent Advances in Immunological Landscape and Immunotherapeutic Agent of Nipah Virus Infection.

Chakraborty C, Saha S, Bhattacharya M Cell Biochem Biophys. 2024; 82(4):3053-3069.

PMID: 39052192 DOI: 10.1007/s12013-024-01424-4.

AttABseq: an attention-based deep learning prediction method for antigen-antibody binding affinity changes based on protein sequences.

Jin R, Ye Q, Wang J, Cao Z, Jiang D, Wang T Brief Bioinform. 2024; 25(4).

PMID: 38960407 PMC: 11221889. DOI: 10.1093/bib/bbae304.

A broadly neutralizing human monoclonal antibody generated from transgenic mice immunized with HCMV particles limits virus infection and proliferation.

Atanasoff K, Parsons A, Ophir S, Lurain N, Kraus T, Moran T J Virol. 2024; 98(7):e0021324.

PMID: 38832789 PMC: 11264687. DOI: 10.1128/jvi.00213-24.

Single domain antibodies from camelids in the treatment of microbial infections.

De Greve H, Fioravanti A Front Immunol. 2024; 15:1334829.

PMID: 38827746 PMC: 11140111. DOI: 10.3389/fimmu.2024.1334829.

A synergistic therapy against influenza virus A/H1N1/PR8 by a HA1 specific neutralizing single-domain V and an RNA hydrolyzing scFv.

Hoang P, Luong Q, Ayun R, Lee Y, Oh K, Kim T Front Microbiol. 2024; 15:1355599.

PMID: 38706966 PMC: 11066198. DOI: 10.3389/fmicb.2024.1355599.

References

Heinz F . Epitope mapping of flavivirus glycoproteins. Adv Virus Res. 1986; 31:103-68. DOI: 10.1016/s0065-3527(08)60263-8. View

Jacobson J, Colman N, Ostrow N, Simson R, Tomesch D, Marlin L . Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis. 1993; 168(2):298-305. DOI: 10.1093/infdis/168.2.298. View

Sloan S, Hanlon C, Weldon W, Niezgoda M, Blanton J, Self J . Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine. 2007; 25(15):2800-10. DOI: 10.1016/j.vaccine.2006.12.031. View

Gilmour J . Expression of neutralizing recombinant human antibodies against Varicella Zoster virus for use as a potential prophylactic. Hybridoma. 2000; 19(2):143-9. DOI: 10.1089/02724570050031185. View

Burton D, Desrosiers R, Doms R, Koff W, Kwong P, Moore J . HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004; 5(3):233-6. DOI: 10.1038/ni0304-233. View

Schmaljohn C, Cui Y, Kerby S, Pennock D, Spik K . Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phage-display combinatorial library. Virology. 1999; 258(1):189-200. PMC: 9631611. DOI: 10.1006/viro.1999.9701. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Simmons C, Bernasconi N, Suguitan A, Mills K, Ward J, Vinh Chau N . Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007; 4(5):e178. PMC: 1880850. DOI: 10.1371/journal.pmed.0040178. View

Glass W, Lim J, Cholera R, Pletnev A, Gao J, Murphy P . Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med. 2005; 202(8):1087-98. PMC: 2213214. DOI: 10.1084/jem.20042530. View

10.

Dimitrov D . Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol. 2004; 2(2):109-22. PMC: 7097642. DOI: 10.1038/nrmicro817. View

11.

Kashmiri S, De Pascalis R, Gonzales N, Schlom J . SDR grafting--a new approach to antibody humanization. Methods. 2005; 36(1):25-34. DOI: 10.1016/j.ymeth.2005.01.003. View

12.

Li H, Sethuraman N, Stadheim T, Zha D, Prinz B, Ballew N . Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol. 2006; 24(2):210-5. DOI: 10.1038/nbt1178. View

13.

Carter P . Potent antibody therapeutics by design. Nat Rev Immunol. 2006; 6(5):343-57. DOI: 10.1038/nri1837. View

14.

Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G . A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993; 67(11):6642-7. PMC: 238102. DOI: 10.1128/JVI.67.11.6642-6647.1993. View

15.

de Carvalho Nicacio C, Lundkvist A, Sjolander K, Plyusnin A, Salonen E, Bjorling E . A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. J Med Virol. 2000; 60(4):446-54. DOI: 10.1002/(sici)1096-9071(200004)60:4<446::aid-jmv13>3.0.co;2-v. View

16.

Allander T, Drakenberg K, Beyene A, Rosa D, Abrignani S, Houghton M . Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol. 2000; 81(Pt 10):2451-2459. DOI: 10.1099/0022-1317-81-10-2451. View

17.

Reichert J . Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs. 2007; 21(1):1-7. PMC: 7100544. DOI: 10.2165/00063030-200721010-00001. View

18.

Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C . Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005; 11(6):615-22. DOI: 10.1038/nm1244. View

19.

Park S, Jeong Y, Lee Y, Kim I, Seo S, Kim E . Hepatitis B virus-neutralizing anti-pre-S1 human antibody fragments from large naïve antibody phage library. Antiviral Res. 2005; 68(3):109-15. DOI: 10.1016/j.antiviral.2005.06.012. View

20.

Bowley D, Labrijn A, Zwick M, Burton D . Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage. Protein Eng Des Sel. 2007; 20(2):81-90. DOI: 10.1093/protein/gzl057. View